Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2021)
41 slides from Starpharma's shareholder meeting presentation, Nov 30, 2021
Slide 1: AGM Chairman's address and CEO's presentation
AGM Chairman’s address and CEO’s presentation For personal use only Melbourne, Australia; 30 November 2021: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbour
Slide 2: Chairman's Address
Chairman’s Address Starpharma Holdings Limited Annual General Meeting 30 November 2021 For personal use only Good morning, On behalf of the Board of Directors, it is my pleasure to welcome you to Starpharma’s 2021 Annual General Meeting. Before I give my formal address, on behalf of the Board, I wan
Slide 3: Chairman's Address (continued)
Gamma – as well as other respiratory viruses, including influenza and RSV, and pandemic viruses, SARS, and MERS in laboratory studies. New data on VIRALEZE™ and SPL7013 has also been published in prestigious international and peer reviewed scientific journals this year, highlighting the product’s im
Slide 4: Chairman's Address (continued)
heavily pre-treated patients. These efficacy signals, which include significant reductions in measurable tumours for some patients, are particularly important for those who have failed multiple previous treatments and have few options. The results from these phase II trials have the potential to del
Slide 5: Annual General Meeting November 2021
For personal use only Annual General Meeting 30 November 2021 Dr Jackie Fairley, CEO ASX:SPL OTC:SPHRY 1
Slide 6: Important notice and disclaimer
For personal use only Important notice and disclaimer This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward- looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”
Slide 7: Dendrimer platform delivers significant optionality
Starpharma’s dendrimer platform delivers significant optionality with multiple potential revenue streams, valuable products & clinical-stage assets For personal use only Through innovative research and DEP® - A valuable VIRALEZE™ Antiviral development, Starpharma is creating proprietary nanoparticle
Slide 8: Starpharma's portfolio
Starpharma’s portfolio: High-value assets including VIRALEZE™, VivaGel® products on market, and multiple DEP® clinical-stage assets For personal use only Internal DEP® products Marketed Products Preclinical Phase 1 Phase 2 DEP® irinotecan DEP® cabazitaxel DEP® docetaxel DEP® radiopharma- Partnered D
Slide 9: 2021 Highlights
2021 HIGHLIGHTS AstraZeneca expanded Starpharma announced VIRALEZE™ antiviral Testing Starpharma awarded and expedited its AZD0466 positive DEP® phase 2 nasal spray registered for for VIRALEZE™ $1 million by the Australian clinical program into a interim results in prostate sale in UK/Euro
Slide 10: Financial summary
Financial summary Strong balance sheet with $53.4M cash (30 September 2021) For personal use only FY21 FY20 Key Financial Data FY21 Result A$M A$M Revenue 2.2 6.6 • Revenue: , note FY20 included $4.3M (US$3M) AstraZeneca DEP® milestone Other Income 1.3 0.6 • Other Income includes $0.9M MRFF grant i
Slide 11: DEP platform - broad applicability and exceptional optionality
Starpharma’s DEP® platform - broad applicability and exceptional optionality For personal use only Multiple DEP® products and therapeutic areas - partnered and internal programs Antibody Drug Chemotherapeutics Radiotheranostics Non-oncology Conjugates (ADCs) • Franchise extension • Radiotheranostic
Slide 12: Partnering creates significant value and optionality
DEP® partnering creates significant value and optionality Starpharma’s DEP® platform enhances the commercial and therapeutic value of a wide range of drugs, creating multiple potential revenue streams and significant IP leverage For personal use only AstraZeneca’s novel DEP® nanoparticle DEP® platfo
Slide 13: AstraZeneca's novel DEP nanoparticle AZD0466
AstraZeneca’s novel DEP® nanoparticle AZD0466 For personal use only • AZD0466 is a highly optimised DEP® nanoparticle formulation of AstraZeneca’s dual Bcl-2/xL inhibitor (AZD4320) • Dual Bcl-2/xL inhibition with AZD0466 has potential for broader activity than the marketed Bcl-2 inhibitor, venetocla
Slide 14: Partnerships with leading antibody drug conjugate companies
Starpharma has a number of partnerships with leading antibody drug conjugate companies For personal use only Starpharma’s DEP® technology represents a valuable partnering platform which has the potential to generate revenue through royalties and milestones Starpharma has a DEP® research agreement wi
Slide 15: DEP platform delivers multiple benefits in ADCs
DEP® platform delivers multiple benefits and unique flexibility in Antibody Drug Conjugates (ADCs) For personal use only Starpharma’s DEP® technology provides advantages, including enhanced efficacy, over conventional ADCs Starpharma’s DEP® ADCs 1600 Treatment 1600 Treatment Tumour Volume (mm3) Phas
Slide 16: Internal oncology programs
DEP® internal oncology programs Multiple clinical-stage assets with high commercial value potential For personal use only PHASE 2 PHASE 2 PHASE 2 DEP® DOCETAXEL: DEP® CABAZITAXEL: DEP® IRINOTECAN: Enhanced version of Enhanced version of Improved version of docetaxel (Taxotere®) – leading prostate ir
Slide 17: DEP cabazitaxel: phase 2 trial ongoing, encouraging efficacy signals
DEP® cabazitaxel: phase 2 trial ongoing, encouraging efficacy signals Enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®) For personal use only 62-year-old man Trial status: Phase 2, ongoing, 51 patients recruited with metastatic prostate cancer showed 87% Efficacy signals Prosta
Slide 18: DEP cabazitaxel Phase 2 positive interim results in prostate cancer
DEP® cabazitaxel Phase 2 Trial – Positive Interim Results in Prostate Cancer Cohort For personal use only Prostate cancer is About cabazitaxel (Jevtana®) DEP® cabazitaxel - Phase 2 interim results in prostate the 2nd most cancer cohort • Primary indication – prostate cancer common cancer in 2 FDA “B
Slide 19: DEP cabazitaxel: Advantages over Jevtana
DEP® cabazitaxel: Advantages over Jevtana® many commercial parallels with Abraxane® (paclitaxel) For personal use only Jevtana® DEP® cabazitaxel Abraxane® (Improved nanoparticle 2020 sales formulation) • Abraxane® is an improved US$600M nanoparticle formulation of Taxol 1. Neutropenic Deaths (paclit
Slide 20: Cabazitaxel: clinical case study in prostate cancer
DEP® cabazitaxel: clinical case study in prostate cancer For personal use only 80-year-old man with stage IV prostate cancer • Progressed following 33 cycles/months of 3 different prior anti-cancer therapies CT Scans of Lymph Node metastasis • 7 cycles of DEP® cabazitaxel to date BASELINE POST-TREAT
Slide 21: Cabazitaxel: clinical case study in oesophageal cancer
DEP® cabazitaxel: clinical case study in oesophageal cancer For personal use only Oesophageal cancer 73-year-old man with stage IV oesophageal cancer • Oesophageal cancer is the • Cancer progressed following extensive radiation therapy and chemotherapy sixth leading cause of cancer- related mortalit
Slide 22: DEP docetaxel: phase 2 trial ongoing, encouraging efficacy signals
DEP® docetaxel: phase 2 trial ongoing, encouraging efficacy signals Enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer For personal use only Trial status: Phase 2 trial ongoing, 65 patients recruited^ The same tumour targeting observed with Efficacy signals Lu
Slide 23: Docetaxel clinical case studies: monotherapy and in combination
DEP® docetaxel clinical case studies: monotherapy and in combination For personal use only 66-year-old man: stage IV oesophageal cancer 74-year-old man with stage IV pancreatic cancer with liver metastases (monotherapy) (in combination with gemcitabine) Oesophageal cancer is the sixth leading cause
Slide 24: DEP irinotecan: phase 2 trial underway, encouraging efficacy signals
DEP® irinotecan: phase 2 trial underway, encouraging efficacy signals Enhanced version of irinotecan (Camptosar®) - predominantly used for colorectal cancer For personal use only Trial status: Phase 2, ongoing, 61 patients recruited Results from DEP® irinotecan phase 1 trial: Efficacy signals Breast
Slide 25: Irinotecan: clinical case study in ovarian cancer
DEP® irinotecan: clinical case study in ovarian cancer For personal use only 55-year-old woman with heavily pre-treated stage IV ovarian cancer Ovarian cancer has the lowest survival rate of women’s BASELINE POST TREATMENT cancer* with a 5-year survival of ~17% for Stage IV • Patient was heavily pre
Slide 26: Irinotecan: clinical case study in oesophageal cancer
DEP® irinotecan: clinical case study in oesophageal cancer For personal use only Oesophageal cancer 60-year-old man with stage IV oesophageal cancer • Oesophageal cancer is the BASELINE sixth leading cause of cancer- related mortality worldwide.1 • Pre-treated with 3 different prior anti-cancer agen
Slide 27: A valuable platform with application to multiple radiotheranostics
DEP® - a valuable platform with application to multiple radiotheranostics For personal use only • Radiotheranostics is a rapidly developing area of cancer treatment and diagnosis with sales estimated to grow to $12–15 billion by 2030^ • Significant corporate activity in recent years • Starpharma’s D
Slide 28: DEP as a platform for radiotheranostics
DEP® as a platform for radiotheranostics For personal use only Targeted DEP® theranostics offer multiple benefits: • Flexibility in size and structure of nanoparticle (allowing different targeting groups and pharmacokinetics) • Enhanced tumour accumulation due to the EPR effect (10x nanobody alone)
Slide 29: Multiple novel radiotheranostic candidates
Starpharma has developed multiple novel radiotheranostic (radiodiagnostics and radiotherapeutics) candidates For personal use only DEP® radiodiagnostic DEP® radiotherapeutics DEP® HER2-zirconium DEP® lutetium DEP® HER2-lutetium • DEP® HER2-zirconium achieved significant • DEP® lutetium showed signif
Slide 30: VIRALEZE antiviral nasal spray is virucidal against SARS-CoV-2
VIRALEZE™ antiviral nasal spray is virucidal, inactivating >99.9% of SARS-CoV-2 (the coronavirus that causes COVID-19) For personal use only • Broad-spectrum antiviral nasal spray containing 1% SPL7013, VIRALEZE™ advantages shown in laboratory studies to inactivate respiratory viruses, including >99
Slide 31: VIRALEZE launched in UK/EU, further registrations and launches
VIRALEZE™ antiviral nasal spray launched in UK/EU 1HCY21, further registrations achieved, and further launches to follow For personal use only VIRALEZE™ partnered with VIRALEZE™ is registered in ADMENTA Italia Group for the Europe, India, and New sales and distribution of Zealand. VIRALEZE™ in Itali
Slide 32: VIRALEZE distribution and supply
VIRALEZE™ distribution and supply For personal use only • VIRALEZE™ is manufactured in Europe VIRALEZE™ distribution and supply in Vietnam utilising an existing qualified contract manufacturing organisation (CMO) • Starpharma signed an initial supply contract and received first orders for 100,000 un
Slide 33: How VIRALEZE works and why it maintains activity despite mutations
How VIRALEZE™ works and VIRALEZE™ (SPL7013) has potent and why it maintains activity virucidal activity against multiple variants despite mutations of SARS-CoV-2 For personal use only • SARS-CoV-2 infects human cells by • Antiviral testing has confirmed SPL7013 (VIRALEZE™ antiviral agent) has potent
Slide 34: SPL7013 antiviral activity across respiratory viruses
SPL7013 has potent antiviral activity VIRALEZE™ protects against across a wide range of respiratory viruses infection in SARS-CoV-2 challenge model For personal use only • Extensive research has been conducted at The Scripps Research VIRALEZE™ protected animals and significantly reduced their viral
Slide 35: VivaGel BV - treatment and prevention of recurrent BV
VivaGel® BV - a breakthrough product for the treatment of BV and prevention of recurrent BV For personal use only • Bacterial vaginosis or BV is the most common vaginal infection worldwide, affecting 1 in 3 women • BV is caused by an imbalance of naturally occurring normal bacterial vaginal flora an
Slide 36: VivaGel BV licensed in >160 countries and approved in >45
VivaGel® BV is licensed in >160 countries around the world and approved in >45 countries with multiple other submissions underway For personal use only Launched in the UK, Europe, Asia, South Africa, CY21: Australia & NZ Pre-launch preparations Further launches and regulatory submissions NORTH EUROP
Slide 37: VivaGel Condom
VivaGel® Condom For personal use only • The VivaGel® condom incorporates SPL7013 antiviral, which has demonstrated activity in HIV, HSV-2, HPV • Starpharma continues to support its marketing SPL7013 partners, Okamoto (Japan/Asia), LifeStyles, and Sky and Land (China), to progress registration and co
Slide 38: Key value drivers and outlook - DEP platform
Key value drivers and outlook - DEP® platform For personal use only Progress and completion of Progress with existing partnered DEP® docetaxel, DEP® DEP® programs, including with cabazitaxel & DEP® irinotecan Merck & Co., Inc., & Chase Sun phase 2 trials; progress value- adding combination studi
Slide 39: Key value drivers and outlook - VIRALEZE and VivaGel BV
Key value drivers and outlook - VIRALEZE™ and VivaGel® BV For personal use only Further roll-out of VIRALEZE™ Further distribution & marketing Antiviral Nasal Spray in registered arrangements with commercial regions partners Further VIRALEZE™ Continued testing of SPL7013 registrations in oth
Slide 40: Starpharma's Commitment to ESG
Starpharma’s Commitment to ESG For personal use only ENVIRONMENT GOVERNANCE Appropriate systems in Starpharma Compliance with No breaches of: DIRECTOR place to comply with is committed INDEPENDENCE - Code of Conduct relevant Federal, State, to conducting and Local environment its operations in - Ant
Slide 41: Investor Relations Contact
For Investor Relations Queries Contact: For personal use only Dr Jackie Fairley, CEO +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 www.Starpharma.com ASX:SPL OTC:SPHRY 37
Starpharma Holdings — Shareholder Meeting (November 2021) on 6ix